Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

  title={Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis},
  author={Stefan Leucht and Andrea Cipriani and Loukia Maria Spineli and Dimitris Mavridis and Deniz {\"O}rey and Franziska Richter and Myrto Samara and Corrado Barbui and Rolf R. Engel and John R. Geddes and Werner Kissling and Marko Paul Stapf and Bettina L{\"a}ssig and Georgia Salanti and John M. Davis},
  journal={The Lancet},

Figures from this paper

Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.

Insufficient evidence exists on which antipsychotic is more efficacious for patients with treatment-resistant schizophrenia, and blinded RCTs-in contrast to unblinded, randomized effectiveness studies-provide little evidence of the superiority of clozapine compared with other second-generation antipsychotics.

Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.

There were some significant differences between clozapine combination strategies for global and mental state (clinically significant response and change), and there were data for leaving the study early and weight gain, but no data for service utilisation and quality of life.

Comparative efficacy and safety of antipsychotics in the treatment of schizophrenia: a network meta-analysis in a Japanese population

Diverse hierarchies in safety outcomes also support the implication that individual risk expectations for adverse events can guide clinical decisions, and additional efficacy and safety data are required to fully obtain a conclusive understanding.

Lithium for schizophrenia.

The evidence base for the use of lithium alone as an effective treatment for schizophrenia, schizophrenia-like psychoses and schizoaffective psychoses is limited to 22 studies, and the overall methodological quality of the included sample was rather low.

Antipsychotic combinations in schizophrenia

A systematic review and meta-analysis of randomised controlled trials investigated the efficacy and tolerability of AP combination v. monotherapy in schizophrenia and showed that the combination of two APs was more effective thanmonotherapy in terms of symptom reduction.



Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotic drugs.

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.

The findings suggest that some second-generation antipsychotics may be somewhat more efficacious than others, but the limitations of meta-analysis must be considered in tailoring drug treatment to the individual patient.

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

It is concluded that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds.

Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.

Differences in efficacy data over an 18-year period from randomized placebo-controlled trials submitted in support of new drug applications for the treatment of schizophrenia are explored and differences in results between trials conducted in North America and elsewhere are explored.

Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications

Clear benefits of FGAs versus SGAs for treating schizophrenia remain inconclusive because of variation in assessing outcomes and lack of clinically important differences for most comparisons.

Perphenazine for schizophrenia.

Perphenazine showed similar effects and adverse events as several of the other pooled antipsychotic drugs, but interpretation of findings of the review was limited by poor reporting and the use of 24 different comparator antipsychotics in the 20 trials.

Haloperidol dose for the acute phase of schizophrenia.

Doses of haloperidol in the range of > 3 to 7.5 mg/day had a lower rate of development of clinically significant extrapyramidal adverse effects than higher doses, but further research is needed regarding the efficacy and tolerability of the lower dose ranges.